netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Chapter Links...
 Details...
06.01.02.03  Expand sub section  Other antidiabetic drugs
06.01.02.03  Expand sub section  Thiazolidinediones (Glitazones)
Pioglitazone (Actos®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets 
Link  MHRA Pioglitazone and bladder cancer Aug 2011
Link  MHRA Pioglitazone Cardiovascular Safety Jan 2011
   
06.01.02.03  Expand sub section  Dipeptidylpeptidase-4 inhibitors (Gliptins)
 note 

Dipeptidylpeptidase-4 inhibitors (Gliptins)

Acute pancreatitis associated with gliptins has been reported. Inform patients of the symptoms of acute pancreatitis. If pancreatitis is suspected, the DPP-4 inhibitor should be discontinued.

• Only continue DPP-4 inhibitor therapy if the person has had a beneficial metabolic response (a reduction of at least 0.5 percentage points in HbA1c in 6 months) –as per NICE CG87.

• Monotherapy: Saxagliptin, Sitagliptin and Linagliptin – only if metformin contra-indicated or not tolerated. Alogliptin is not licensed for monotherapy.
• See individual SPCs for details of dosage in renal impairment.

GMMMG IPNTS: DPP-4 inhibitors (‘The Gliptins’) for the treatment of type 2 diabetes mellitus. Feb 2014

Alogliptin (Vipidia®)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green 1
Tablets

 
Linagliptin (Trajenta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green 1
Tablets

note First choice 'Gliptin' for patients with moderate or severe renal impairment (CrCl<50ml/min, eGFR<59ml/min)
 
   
Saxagliptin (Onglyza®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green 1
Tablets

note For established patients only. Alogliptin is first line.
 
   
Sitagliptin (Januvia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green 1
Tablets

note For established patients only. Alogliptin is first line.

 
   
06.01.02.03  Expand sub section  GLP-1 receptor mimetics
 note 

GLP-1 mimetics should only be considered as third-line therapy in accordance with NICE CG87/TA203/TA248).

GLP-1 mimetics should only be continued if reduction of at least 1% point in HbA1c AND a weight loss of at least 3% of initial body weight at 6 months

Exenatide (Byetta®)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green 1
Disposable pen 
Liraglutide (Victoza®)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green 1
Disposable pen 
Lixisenatide (Lyxumia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green 1
Disposable pen 
Link  NICE ESNM26 Type 2 diabetes: lixisenatide May 2013
   
Exenatide Prolonged Release (Bydureon®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green 1
Vial

Once weekly preparation 
Link  NICE TA248: Exenatide Prolonged Release
   
06.01.02.03  Expand sub section  SGLT-2 inhibitors to top
 note 

In individuals with type 2 diabetes and established cardiovascular disease, SGLT-2 inhibitors with proven cardiovascular benefit (currently empagliflozin and canagliflozin) should be considered

Empagliflozin (Jardiance®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets 
Link  NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Dapagliflozin (Forxiga®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary

Tablets

 
Link  GMMMG NTS: SGLT2 Inhibitors for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Link  NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
   
Canagliflozin (Invokana®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets 
Link  GMMMG NTS: SGLT2 Inhibitors for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.
Link  NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
06.01.02.03  Expand sub section  Other antidiabetic agents
 note 

Nateglinide only licensed for use in combination with metformin. Cautioned in moderate hepatic impairment.

Repaglinide can be given as monotherapy or in combination with metformin. It should be avoided in patients >75 years old and in patients with severe liver disease.

Repaglinide (Prandin®)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Tablets 
Nateglinide (Starlix®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets 
   
Acarbose (Glucobay®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets 
   
06.01.02.03  Expand sub section  Other
 ....
 Non Formulary Items
Linagliptin/ metformin  (Jentadueto®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Pioglitazone and Metfomin  (Competact®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Rosiglitazone  (Avandia®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary DISCONTINUED
 
Rosiglitazone and Metformin  (Avandamet®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary DISCONTINUED
 
Saxagliptin and metformin  (Komboglyze®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Sitagliptin and Metformin  (Janumet®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Vildagliptin

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary